drugset / Trial / NCT07464210
Nemtabrutinib, Bortezomib, and Rituximab for WM
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II (2 parts), open-label, single arm, multicenter study to evaluate the efficacy and safety of nemtabrutinib in combination with bortezomib and rituximab
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-08-01
- Completion
- 2030-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nemtabrutinib | Other / unclassified | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |